



#13

AJ
4/17/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 15 2002

TECH CENTER 1600/290

Application of: JERUSSI *et al.*

Application No.: 09/527,442

Group Art Unit: 1621

Filed: March 17, 2000

Examiner: S. BARTS

For: DERIVATIVES OF VENLAFAXINE AND
METHODS OF PREPARING AND USING
THE SAME

Attorney Docket No.: 4821-369

RESPONSE TO RESTRICTION REQUIREMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Office Action mailed February 13, 2002, in which the above-identified application was examined for restriction purposes only. Applicants respectfully request consideration and entry of the following remarks and provisional election in the file of the application. Enclosed herewith is a petition for extension of time with provision for the required fee.

REMARKS

On page 2 of the Office Action, the Examiner requires that Group V, originally set out in previous Office Action dated September 21, 2001, be further restricted to a specific disorder. Applicants provisionally elect, with traverse, claims 27-29 and 52-59, which are directed to methods of treating affective disorders.

However, Applicants respectfully submit that a single search directed to O-desmethylvenlafaxine would encompass all claims in Group V. Accordingly, it is believed that the examination of all claims in Group V would not impose an unreasonable burden on